{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:06Z","timestamp":1749948006523,"version":"3.41.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Study of liquid lopinavir\/ritonavir (LPV\/r) in young infants has been limited by concerns for its safety in neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1106 was a phase IV, prospective, trial evaluating the safety and pharmacokinetics of antiretroviral medications administered according to local guidelines to South African preterm and term infants &lt;3 months of age. Safety evaluation through 24-week follow-up included clinical, cardiac and laboratory assessments. Pharmacokinetic data from P1106 were combined with data from International Maternal Pediatric Adolescent AIDS Clinical Trials Network studies P1030 and P1083 in a population pharmacokinetics model used to simulate LPV exposures with a weight-band dosing regimen in infants through age 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Safety and pharmacokinetics results were similar in 13\/28 (46%) infants initiating LPV\/r &lt;42 weeks postmenstrual age (PMA) and in those starting \u226542 weeks PMA. LPV\/r was started at a median (range) age of 47 (13\u2013121) days. No grade 3 or higher adverse events were considered treatment related. Modeling and simulation predicted that for infants with gestational age \u226527 weeks who receive the weight-band dosing regimen, 82.6% will achieve LPV trough concentration above the target trough concentration of 1.0 \u00b5g\/mL and 56.6% would exceed the observed adult lower limit of LPV exposure of 55.9 \u00b5g\u00b7h\/mL through age 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>LPV\/r oral solution was safely initiated in a relatively small sample size of infants \u226534 weeks PMA and &gt;2 weeks of life. No serious drug-related safety signal was observed; however, adrenal function assessments were not performed. Weight-band dosing regimen in infants with gestational age \u226527 weeks is predicted to result in LPV exposures equivalent to those observed in other pediatric studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004243","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T22:00:24Z","timestamp":1704751224000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Pharmacokinetics of Lopinavir\/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-3432","authenticated-orcid":false,"given":"Adrie","family":"Bekker","sequence":"first","affiliation":[{"name":"From the Family Centre for Research with Ubuntu, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Cotton","sequence":"additional","affiliation":[{"name":"From the Family Centre for Research with Ubuntu, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mae","family":"Cababasay","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative pharmacology, CPSS, AstraZeneca R&D, Waltham, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Moye","sequence":"additional","affiliation":[{"name":"Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Browning","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdose L.","family":"Nakwa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Faculty of Health Sciences, School of Clinical Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Rabie","sequence":"additional","affiliation":[{"name":"From the Family Centre for Research with Ubuntu, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avy","family":"Violari","sequence":"additional","affiliation":[{"name":"Perinatal HIV research Unit, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[{"name":"AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund V.","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1000931","article-title":"Antiretroviral treatment for children with peripartum nevirapine exposure.","volume":"363","author":"Palumbo","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/PEC.0000000000001946","article-title":"Ethanol intoxication of young children.","volume":"35","author":"Gaw","year":"2019","journal-title":"Pediatr Emerg Care"},{"key":"R7-20250614","first-page":"277","article-title":"Propylene glycol toxicity in children.","volume":"19","author":"Lim","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R10-20250614","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00420-17","article-title":"Pharmacokinetics and drug-drug interactions of lopinavir-ritonavir administered with first- and second-line antituberculosis drugs in HIV-Infected children treated for multidrug-resistant tuberculosis.","volume":"62","author":"van der Laan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.qai.0000155203.89350.85","article-title":"Increased dose of lopinavir\/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.","volume":"39","author":"Bergshoeff","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/S2214-109X(15)00163-1","article-title":"Postnatal growth standards for preterm infants: the preterm postnatal follow-up study of the INTERGROWTH-21(st) project.","volume":"3","author":"Villar","year":"2015","journal-title":"Lancet Glob Health"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200101050-00002","article-title":"ABT-378\/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.","volume":"15","author":"Murphy","year":"2001","journal-title":"AIDS"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/INF.0b013e31818cc053","article-title":"Early initiation of lopinavir\/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.","volume":"28","author":"Chadwick","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1097\/QAD.0b013e3282f12060","article-title":"Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART.","volume":"21","author":"Lopriore","year":"2007","journal-title":"AIDS"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/INF.0b013e3181acd17e","article-title":"Twin preterm neonates with cardiac toxicity related to lopinavir\/ritonavir therapy.","volume":"28","author":"McArthur","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2011.915","article-title":"Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.","volume":"306","author":"Simon","year":"2011","journal-title":"JAMA"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/cid\/ciz888","article-title":"Lopinavir-ritonavir impairs adrenal function in infants.","volume":"71","author":"Kariyawasam","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"250716","DOI":"10.1155\/2013\/250716","article-title":"Elimination kinetics of ethanol in a 5-week-old infant and a literature review of infant ethanol pharmacokinetics.","volume":"2013","author":"Ford","year":"2013","journal-title":"Case Rep Med"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2125.2012.04312.x","article-title":"Developmental pharmacokinetics of propylene glycol in preterm and term neonates.","volume":"75","author":"De Cock","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00007691-198709000-00001","article-title":"Propylene glycol pharmacokinetics and effects after intravenous infusion in humans.","volume":"9","author":"Speth","year":"1987","journal-title":"Ther Drug Monit"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.1985.03350350100031","article-title":"Hyperosmolality induced by propylene glycol A complication of silver sulfadiazine therapy.","volume":"253","author":"Fligner","year":"1985","journal-title":"JAMA"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty-eight-week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.","volume":"22","author":"Saez-Llorens","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants.","volume":"359","author":"Violari","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:01:21Z","timestamp":1749945681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004243","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}